Revised forecast
Fiscal year ending March 2026 · Full yearPrevious forecast published 5 February 2026The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
The precision equipment business performed better than expected, a provision for sales rebates in the medical equipment business was reversed due to differences between estimates and actual results, and selling, general and administrative expenses were lower than expected.
| Item | Details |
|---|---|
| Net Sales | ¥6,744 million → ¥6,798 million（+0.8%） |
| Operating profit | ¥368 million → ¥415 million（+12.7%） |
| Ordinary income | ¥291 million → ¥337 million（+15.9%） |
| Profit attributable to owners of the parent | ¥35 million → ¥63 million（+79.4%） |
| Net income per share | 27.98 yen and sen → 50.2 yen and sen |
| Fiscal Period Covered | Fiscal year ending March 2026 |
| Period Covered | Full year |
| Publication date of previous forecast | 5 February 2026 |
| Previous-period results | Consolidated: net sales of ¥7,198 million, operating income of ¥208 million, ordinary income of ¥170 million, net income attributable to owners of the parent of ¥298 million, and earnings per share of ¥235.19. Standalone: net sales of ¥7,079 million, ordinary income of ¥167 million, net income of ¥297 million, and earnings per share of ¥234.59. |
| Reason for the revision | The precision equipment business performed better than expected, a provision for sales rebates in the medical equipment business was reversed due to differences between estimates and actual results, and selling, general and administrative expenses were lower than expected. |
| Dividend forecast revision | The dividend per share was increased by ¥1, from the latest forecast of ¥80.00 to ¥81.00. |
| Consolidated / non-consolidated | Consolidated / non-consolidated (standalone) |
Items this document does not state (1)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The precision equipment business performed better than expected, a provision for sales rebates in the medical equipment business was reversed due to differences between estimates and actual results, and selling, general and administrative expenses were lower than expected. The dividend was increased based on the company’s shareholder return policy, which targets a DOE of 2.8% or higher, and full-year consolidated results.